Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2020 - 12 - 08 tags : Cancer save search
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Published: 2020-12-08 (Crawled : 22:00) - biospace.com/
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy treatment designation
Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium
Published: 2020-12-08 (Crawled : 19:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.23%
H: 3.22%
C: 2.67%
breast cancer cancer symposium
Panbela Therapeutics, Inc. Completes Enrollment in its Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer· Phase 1b Data Expected 1H 2021
Published: 2020-12-08 (Crawled : 16:01) - biospace.com/
PBLA | $1.15 -6.31% 360K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -1.94%
cancer therapy trial pancreatic phase 1b pancreas phase 2b enroll
Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation
Published: 2020-12-08 (Crawled : 16:00) - biospace.com/
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 1.13%
H: 0.04%
C: -0.03%
cancer therapy lung cancer breakthrough therapy grant designation
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
Published: 2020-12-08 (Crawled : 14:05) - globenewswire.com
MNPR | News | $0.688 5.04% 4.8% 78K
|
Health Technology
|
| O: -4.06%
H: 12.8%
C: 11.97%
cancer therapy trial oral mucositis phase 2b
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor
Published: 2020-12-08 (Crawled : 14:02) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy tyrosine kinase inhibitor designation
Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional Cancers
Published: 2020-12-08 (Crawled : 12:00) - globenewswire.com
THTX | $1.32 -12.78% 10K
|
Health Technology
|
| O: -0.45%
H: 4.93%
C: 2.69%
cancer treatment
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.